The examination of the efficacy by adverse reaction changing the treatment with Oxybutynin or Mirabegron on the patient who cannot go on treatment with anticholinergic agent

The examination of the efficacy by adverse reaction changing the treatment with Oxybutynin or Mirabegron on the patient who cannot go on treatment with anticholinergic agent - The examination of the efficacy by adverse reaction changing the treatment with Oxybutynin or Mirabegron on the patient who cannot go on treatment with anticholinergic agent

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019736

Enrollment

100

Registered

2015-11-10

Start date

2015-11-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder

Interventions

using oxybutynin for 12 weeks usin mirabegron for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: want to change the midicine by adverse reaction

Exclusion criteria

Exclusion criteria: contraindication of the medicine acute urinary retension within 12 months residual urine over 100mL urinary infection a1 blacker within 4 weeks

Design outcomes

Primary

Measure	Time frame
satisfaction of the patient	—

Secondary

Measure	Time frame
IPSS,OABSS	—

Countries

Japan

Contacts

Public ContactTeruhiko Tsuru

Shiga University of medical Science Urology

tsuru@belle.shiga-med.ac.jp0775482273

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026